SEC Contract Filing

Filing Date: 2021-11-15

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>bcli-20211030xex10d1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge 9.11.0.85--><!--Created on: 11/15/2021 11:53:05 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Brainstorm Cell Therapeutics Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">4</b><sup style="font-size:7.5pt;font-weight:bold;vertical-align:top;">th </sup><b style="font-weight:bold;">Amendment to the Second Amended and Restated Director Compensation Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(adopted October 28, 2021)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">This 4<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Amendment to the Second Amended and Restated Director Compensation Plan is hereby adopted by the Board of Directors (the &#8220;<b style="font-weight:bold;">Board</b>&#8221;) of Brainstorm Cell Therapeutics Inc. (the &#8220;<b style="font-weight:bold;">Corporation</b>&#8221;) and amends the Second Amended and Restated Director Compensation Plan of the Corporation dated July 9, 2014, as amended by the 1<sup style="font-size:7.5pt;vertical-align:top;">st </sup>Amendment to the Second Amended and Restated Director Compensation Plan dated April 29, 2015, the 2<sup style="font-size:7.5pt;vertical-align:top;">nd</sup>&#160;Amendment to the Second Amended and Restated Director Compensation Plan dated February 26, 2017 and the 3<sup style="font-size:7.5pt;vertical-align:top;">rd</sup> Amendment to the Second Amended and Restated Director Compensation Plan dated July 13, 2017 (as amended, the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;), with effect from the date of adoption by the Board, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Section 2 of the Plan be amended and restated in its entirety as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Eligible Participants.</b>&#160;Any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries or affiliates (an &#8220;<b style="font-weight:bold;">Independent Director</b>&#8221;) is an eligible participant. However, Dr. June S. Almenoff and Dr. Menghisteab Bairu shall not be entitled to receive annual director awards under the Plan, but are entitled to committee compensation under the Plan in the event that they qualify for and serve as a member of any committee of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Section 13 of the Plan be amended and restated in its entirety as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Right to Any Other Compensation</b>. Other than with respect to Dr. June S. Almenoff and Dr. Menghisteab Bairu, this Plan constitutes the full and complete compensation to an Independent Director for all services as a director of the Corporation, whether as a member of the Board of Directors, a member of a committee of the Board of Directors, or as Chairperson of the Board of Directors.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>